octatricontanoic acid | 68947-62-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: octatricontanoic acid
• 英文别名: octatriacontanoic acid；Octatriacontansaeure
• CAS: 68947-62-6
• 化学式: C₃₈H₇₆O₂
• 分子量: 565.02
• InChiKey: AJQRZOBUACOSBG-UHFFFAOYSA-N

物化性质

• 沸点：
  543.87°C (rough estimate)
• 密度：
  0.8723 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  18.3
• 重原子数：
  40
• 可旋转键数：
  36
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.97
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 生成 octatricontanoic acid
  参考文献：
  名称：

  Franck; Collins; Piper, Proceedings of the Royal Society of London, Series A: Mathematical, Physical and Engineering Sciences, 1937, vol. 158, p. 694

  摘要：

  DOI：

文献信息

• [EN] LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS<br/>[FR] PROMÉDICAMENTS LIPIDIQUES ORIENTANT VERS LE SYSTÈME LYMPHATIQUE
  申请人：ARIYA THERAPEUTICS INC

  公开号：WO2019046491A1

  公开（公告）日：2019-03-07

  The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a provided lipid prodrug or a pharmaceutical composition thereof.

  本发明提供了淋巴系统定向脂质前药，其制药组合物，制备这种前药和组合物的方法，以及改善作为脂质前药一部分的治疗剂的生物利用度或其他性质的方法。本发明还提供了治疗疾病、紊乱或症状的方法，包括向需要的患者施用所提供的脂质前药或其制药组合物。
• [EN] LIPID PRODRUGS OF PREGNANE NEUROSTEROIDS AND USES THEREOF<br/>[FR] PROMÉDICAMENTS LIPIDIQUES DE NEUROSTÉROÏDES DE PRÉGNANE ET LEURS UTILISATIONS
  申请人：PURETECH HEALTH LLC

  公开号：WO2020028787A1

  公开（公告）日：2020-02-06

  The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

  本发明提供了淋巴系统定向脂质前药，以及其制药组合物、生产这种前药和组合物的方法，以及改善作为脂质前药一部分的治疗剂的生物利用度或其他性质的方法。本发明还提供了治疗疾病、紊乱或症状的方法，包括向需要的患者施用所述的脂质前药或其制药组合物。
• [EN] LIPID PRODRUGS OF NEUROSTEROIDS<br/>[FR] PROMÉDICAMENTS LIPIDIQUES DE NEUROSTÉROÏDES
  申请人：PURETECH LYT INC

  公开号：WO2021159021A1

  公开（公告）日：2021-08-12

  The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

  本发明提供了淋巴系统导向的脂质前药、其药物组合物、制备此类前药和组合物的方法，以及提高包含在脂质前药中的治疗剂的生物利用度或其他特性的方法。本发明还提供了治疗如本文所述的疾病、紊乱或状况的方法，包括向有需要的患者施用所述的脂质前药或其药物组合物。
• [EN] COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES CHARACTERIZED BY INSUFFICIENT PANTOTHENATE KINASE ACTIVITY<br/>[FR] COMPOSITIONS ET MÉTHODES UTILES DANS LE TRAITEMENT DE MALADIES SE CARACTÉRISANT PAR UNE ACTIVITÉ INSUFFISANTE DE LA PANTOTHÉNATE KINASE
  申请人：ACIES BIO D O O

  公开号：WO2017218963A1

  公开（公告）日：2017-12-21

  Methods and pharmaceutical compositions for use in treating diseases associated with insufficient activity of the pantothenate kinase enzyme (e.g., CASTOR diseases) are disclosed. The methods and compositions involve an effective amount of an active derivative of 4'-phosphopantetheine.

  本发明揭示了用于治疗与泛酰胺激酶酶活性不足相关疾病（例如CASTOR疾病）的方法和药物组合物。这些方法和组合物涉及有效量的4'-磷酰泛酰胺的活性衍生物。
• [EN] LIPID PRODRUGS OF CELECOXIB AND USES THEREOF<br/>[FR] PROMÉDICAMENTS LIPIDIQUES DE CÉLÉCOXIB ET LEURS UTILISATIONS
  申请人：UNIV MONASH

  公开号：WO2021051172A1

  公开（公告）日：2021-03-25

  The present invention provides methods of treating metabolic diseases including obesity, insulin resistance and type 2 diabetes with inhibitors of COX-2 or VEGFR and lipid prodrugs of COX-2 inhibitors, in particular celecoxib lipid prodrugs, that promote transport of the pharmaceutical agent to the lymphatic system and which enhance release of the parent agent.

  本发明提供了一种治疗代谢性疾病，包括肥胖、胰岛素抵抗和2型糖尿病的方法，使用COX-2或VEGFR的抑制剂以及COX-2抑制剂的脂质前药，特别是促进药物剂运送到淋巴系统并增强母药释放的Celecoxib脂质前药。